Suppr超能文献

中医药治疗心肌纤维化的研究进展

Research Progress of Traditional Chinese Medicine in Treatment of Myocardial fibrosis.

作者信息

Ren Chunzhen, Liu Kai, Zhao Xinke, Guo Huan, Luo Yali, Chang Juan, Gao Xiang, Lv Xinfang, Zhi Xiaodong, Wu Xue, Jiang Hugang, Chen Qilin, Li Yingdong

机构信息

School of Traditional Chinese and Western Medicine, Gansu University of Chinese Medicine, Lanzhou, China.

Affiliated Hospital of Gansu University of Chinese Medicine, Lanzhou, China.

出版信息

Front Pharmacol. 2022 Jun 8;13:853289. doi: 10.3389/fphar.2022.853289. eCollection 2022.

Abstract

Effective drugs for the treatment of myocardial fibrosis (MF) are lacking. Traditional Chinese medicine (TCM) has garnered increasing attention in recent years for the prevention and treatment of myocardial fibrosis. This Article describes the pathogenesis of myocardial fibrosis from the modern medicine, along with the research progress. Reports suggest that Chinese medicine may play a role in ameliorating myocardial fibrosis through different regulatory mechanisms such as reduction of inflammatory reaction and oxidative stress, inhibition of cardiac fibroblast activation, reduction in extracellular matrix, renin-angiotensin-aldosterone system regulation, transforming growth Factor-β1 (TGF-β1) expression downregulation, TGF-β1/Smad signalling pathway regulation, and microRNA expression regulation. Therefore, traditional Chinese medicine serves as a valuable source of candidate drugs for exploration of the mechanism of occurrence and development, along with clinical prevention and treatment of MF.

摘要

目前缺乏治疗心肌纤维化(MF)的有效药物。近年来,中药在心肌纤维化的防治方面日益受到关注。本文从现代医学角度阐述了心肌纤维化的发病机制及研究进展。报告表明,中药可能通过不同的调节机制发挥改善心肌纤维化的作用,如减轻炎症反应和氧化应激、抑制心脏成纤维细胞活化、减少细胞外基质、调节肾素-血管紧张素-醛固酮系统、下调转化生长因子-β1(TGF-β1)表达、调节TGF-β1/Smad信号通路以及调节微小RNA表达等。因此,中药是探索心肌纤维化发生发展机制以及临床防治的宝贵候选药物来源。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e50c/9213783/67f2295a0d37/fphar-13-853289-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验